Remove Cannabis Remove Conditions Remove DEA Remove Safety
article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

As cannabis enthusiasts, we’re all too familiar with the stigma surrounding its use and the hoops that have to be jumped through to get it into medical research trials. But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. So what gives?

DEA 98
article thumbnail

Veterans Urge Biden To Reschedule Cannabis, But Some Lawmakers Express Concerns

Veriheal

As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. The men and women who served in the U.S. Armed Forces often face difficult physical and mental challenges upon returning home.

DEA 99
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

DEA 66
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51
article thumbnail

DEA Chief of Operations, Christopher Evans, Sworn In By AG Barr To Presidential Commission on Law Enforcement and the Administration of Justice

Cannabis Law Report

It also directs the Commission to research “important current issues facing law enforcement and the criminal justice system,” and recommends a variety of subjects for study, such as, but not limited to” There is no direct mention of cannabis but a senior DEA appointment we would suggest is a message in itself. WASHINGTON, D.C.

DEA 69
article thumbnail

A Strategy for Rescheduling Psilocybin

Canna Law Blog

To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder.

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA).